The influence of clopidogrel on ischemia diagnosed by myocardial perfusion stress testing

Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology
Ion S JovinFrans J Th Wackers

Abstract

Clopidogrel is a platelet adenosine receptor antagonist which can influence coronary vascular tone and thus can potentially interfere with myocardial perfusion imaging. We investigated whether clopidogrel can hamper the diagnosis of ischemia in patients undergoing myocardial perfusion testing. Data from a database of 6349 myocardial perfusion stress tests were analyzed. Using a propensity analysis, patients who were taking clopidogrel were compared with patients not taking clopidogrel for the presence of reversible perfusion defects on myocardial single-photon emission computed tomography scans. Of the 6349 tests, the stress technique was adenosine in 2713 patients and exercise in 3636. At the time of the stress test, 277 (4.3%) of the patients were taking clopidogrel. The odds ratio (OR) for patients taking clopidogrel to have a reversible perfusion defect was 2.75 (95% confidence interval [CI] 2.09-3.62; P < .01). After adjusting for the propensity to take clopidogrel, the OR was 1.06 (CI 0.76-1.49; P = .73) for patients undergoing adenosine stress tests and 1.60 (CI 0.85-3.00; P = .14) for patients undergoing exercise stress tests. We found no evidence that the use of clopidogrel decreases the likelihood of ischemia on adeno...Continue Reading

References

Nov 1, 1990·Circulation·R F WilsonD D Laxson
Feb 12, 1998·Annals of Internal Medicine·D B Rubin
May 18, 1999·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Y H LiuF J Wackers
Nov 13, 2002·Journal of the American College of Cardiology·Laurent M RiouDavid K Glover
Dec 21, 2002·Current Cardiology Reports·Sachin M NavareGary V Heller
Oct 18, 2003·Journal of the American College of Cardiology·Raymond TailleferGary V Heller
May 25, 2004·Expert Opinion on Investigational Drugs·Jean-Marc Herbert
Aug 17, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Anna-Karin WihlborgDavid Erlinge
Oct 21, 2004·JAMA : the Journal of the American Medical Association·Huyen Tran, Sonia S Anand
Jan 1, 2005·Prostaglandins, Leukotrienes, and Essential Fatty Acids·A JakubowskiR J Gryglewski
Jan 22, 2005·Journal of Clinical Pharmacy and Therapeutics·S GreenfieldT Marshall
Apr 27, 2005·Seminars in Thrombosis and Hemostasis·Pierre Savi, Jean-Marc Herbert
Mar 15, 2006·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHARISMA Investigators
Aug 9, 2011·Journal of Cardiovascular Pharmacology·Shantu S BundhooPhilip E James
Nov 22, 2011·Current Atherosclerosis Reports·Luke KimDmitriy N Feldman
Feb 4, 2012·Journal of the American College of Cardiology·Andrew J Einstein
Feb 18, 2014·Heart, Lung & Circulation·Scott R WilloughbyMatthew I Worthley
Mar 22, 2014·Expert Review of Cardiovascular Therapy·Shaun BhattyIon S Jovin
Nov 18, 2014·The New England Journal of Medicine·Laura MauriUNKNOWN DAPT Study Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.